Abstract
In this issue of Blood, McLaughlin et al demonstrate the safety and efficacy of donor-derived Epstein-Barr virus (EBV) latent membrane protein (LMP)-specific T cells to prevent relapse of aggressive EBV-positive B- or T/NK-cell lymphomas following allogeneic hematopoietic stem cell transplantation (HSCT).
Original language | English |
---|---|
Pages (from-to) | 2315-2316 |
Number of pages | 2 |
Journal | Blood |
Volume | 132 |
Issue number | 22 |
DOIs | |
Publication status | Published - 29 Nov 2018 |